Targeted therapy for aggressive prostate cancer with PTEN loss

Precision Neoadjuvant Therapy for High Risk Localized Prostate Cancer with PTEN Loss

NIH-funded research Portland VA Medical Center · NIH-11118672

This study is testing a new treatment for men with high-risk localized prostate cancer that has lost a specific gene, aiming to combine hormone therapy with a special drug before surgery to help shrink the cancer and improve outcomes.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionPortland VA Medical Center NIH-funded
Lab location1 site (Portland, United States)
Project IDNIH-11118672 on NIH RePORTER

What this research studies

This research focuses on improving treatment for high-risk localized prostate cancer characterized by the loss of the PTEN gene. It aims to combine intensified androgen deprivation therapy with an AKT inhibitor before surgery to reduce cancer presence. By utilizing a personalized approach based on genetic markers, the study seeks to enhance treatment effectiveness and minimize residual cancer after surgery. Patients will be closely monitored throughout the trial to assess the impact of this novel therapy.

Who could benefit from this research

Good fit: Ideal candidates for this research are men diagnosed with high-risk localized prostate cancer exhibiting PTEN loss.

Not a fit: Patients with low-risk prostate cancer or those without PTEN loss may not benefit from this targeted therapy.

Why it matters

Potential benefit: If successful, this research could lead to more effective pre-surgical treatments for aggressive prostate cancer, potentially reducing recurrence rates and improving survival outcomes.

How similar studies have performed: Previous research has shown promising results with similar targeted therapies in prostate cancer, indicating potential for success in this approach.

Where this research is happening

Portland, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions androgen independent prostate cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.